As promising therapeutic targets for anti-cancer treatment, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and activators of its receptor (death receptor 4/5, DR4/5) have attracted considerable attention. Here, TNFRSF10A is linked to cancer.